Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration

Prostate

Volumn 36, Issue 2, 1998, Pages 71-79

  Häggström, Stina ^a   Wikström, Pernilla ^a   Bergh, Anders ^a   Damber, Jan Erik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Castration; Competitive reverse transcription polymerase chain reaction; Prostatic adenocarcinoma; VEGF; Ventral prostate

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CASTRATION; CELL PROLIFERATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; ANIMALS; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION; LYMPHOKINES; MALE; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; RNA-DIRECTED DNA POLYMERASE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 2642608679     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980701)36:2<71::AID-PROS1>3.0.CO;2-H     Document Type: Article

References (57)

1. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed cell death of normal and malignant prostatic cells. J Androl 1992;13:457-464.
2. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostatic carcinoma. Cancer 1994;73:678-687.
3. Pötgens AJG, Westphal HR, de Waal RMW, Ruiter DJ: The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem Hoppe Seyler 1995;376:57-70.
4. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
5. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
6. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48:47-57.
7. Wakui S, Furasato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S, Ushigome S: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J Pathol 1992;168:257-262.
8. O'Brien TS, Harris AL: Angiogenesis in urological malignancy. Br J Urol 1995;76:675-682.
9. McNeal JE, Yemoto CEM: Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol 1996;20:1351-1360.
10. Franck-Lissbrant I, Stattin P, Damber J-E, Bergh A: Vascular density is a predictor of cancer specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
11. Kim JK, Li B, Winer J, Armanani M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844.
12. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-2007.
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
14. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 1993;53:1833-1837.
15. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-1504.
16. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
17. Lekås E, Johansson M, Widmark A, Bergh A, Damber J-E: Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25:309-314.
18. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL: Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor B-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
19. Colville-Nash PR, Willoughby DA: Growth factors in angiogenesis: Current interest and therapeutic potential. Mol Med Today 1997;3:14-23.
20. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233-235.
21. Neufeld G, Tessler S, Gita-Goren H, Cohen T, Levi B-Z: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994;5:89-97.
22. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
23. Melnyk O, Shuman MA, Kim J: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996;56: 921-924.
24. Senger DR, Brown LF, Claffey KP, Dvorak HF: Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1994;14:385-394.
25. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-2333.
26. Jackson MW, Bentel JM, Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-2333.
27. Leung DW, Cachianes G, Kuang W-J, Goeddei CV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
28. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267: 26031-26037.
29. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
30. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-1586.
31. Plouet J, Sordello S, Malavaud B, Ortega N: VEGF and breast cancer. In Calvo F, Crepin M, Magdalenat H (eds): "Breast Cancer. Advances in Biology and Therapeutics." John Libbey Euro-text, 1996:175-181.
32. English HF, Drago JR, Santen RJ: Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. Prostate 1985;7:41-51.
33. Franck-Lissbrant I, Häggström S, Damber J-E, Bergh A: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998;139: 451-456.
34. Westin P, Bergh A, Damber J-E: Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate 1993;22:65-74.
35. Brändström A, Westin P, Bergh A, Cajander S, Damber J-E: Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res 1994;54:3594-3601.
36. Landström M, Damber J-E, Bergh A, Tomic R: Dose/response study of the effects of oestrogens on tumour growth and morphology in Duning R3327 prostatic adenocarcinoma. J Cancer Res Clin Oncol 1992;118:30-34.
37. Celi FS, Zenilman ME, Shuldiner AR: A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res 1993;21:1047.
38. Wikström P, Bergh A, Damber J-E: Expression of transforming growth factor-B receptor type I and II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. Urol Res 1997;25:103-111.
39. Danielson PE, Forss-Petter S, Brow MA, Calawetta L, Douglass J, Milner RJ, Sutcliffe JG: p1b15: A cDNA clone of the rat mRNA encoding cyclophilin. DNA 1988;7:261.
40. Lindström P, Bergh A, Holm I, Damber J-E: Expression of transforming growth factor-β1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Prostate 1996;29:209-218.
41. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-524.
42. Yamane A, Seetharam L, Yamaguchi S, Gotoh N, Takahashi T, Neufeld G, Shibuya M: A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994;9:2683-2690.
43. Haendler B, Hofer B: Characterization of the human cyclophilin gene and of related processed pseudogenes. Eur J Biochem 1990;190:477.
44. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in flk-1 deficient mice. Nature 1995;376:62-66.
45. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
46. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
47. Takahashi A, Sasaki H, Kim SJ, Tobisu K-I, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Tereda M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-4237.
48. Nicol D, Hii S-I, Walsh M, Teh B, Thompson L, Kennett C, Gotley D: Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997;157:1482-1486.
49. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-916.
50. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T: Quantification analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996;77:1101-1106.
51. Berger DP, Herbstritt L, Dengler WA, Marme D, Mertelsmann R, Fiebig HH: Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 1995;6:817-825.
52. Gitay-Goren H, Halaban R, Neufeld G: Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993;190:702-708.
53. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, Smith SK: Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994;51:524-530.
54. Rooman I, Schuit F, Bouwens L: Effect of vascular endothelial growth factor and differentiation of pancreatic ductal epithelium. Lab Invest 1997;76:225-232.
55. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML: Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/ vascular endothelial factor. Lab Invest 1997;76:245-255.
56. Kyprianou N, Isaacs JT: Activation of programmed cell death in rat ventral prostate after castration. Endocrinology 1988;122: 552-561.
57. Brown LF, Yeo K-T, Berse B, Morgentaler A, Dvorak HF, Rosen S: Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 1995;154: 576-579.